January 7, 2011
Biodesix, Inc. announces that Paul Beresford, Ph.D., Vice President, Business Development and Strategic Marketing will present at the 2011 Biotech Showcase conference taking place January 10-12th at the Parc 55 Wyndham in San Francisco, California. Biodesix’ presentation will occur on Monday, January 10th, at 2:15 p.m. ... Read more
November 19, 2010
Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany ... Read more
November 5, 2010 Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors. The Series C round, which included 5 new investors, will support ongoing commercialization activities for the company’s first product VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer ... Read more
June 23, 2010
Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award. Colorado Companies to Watch is a dynamic business recognition program honoring second-stage companies headquartered in the state of Colorado that are developing valuable products and services, creating quality jobs, enriching communities, and ... Read more
June 21, 2010
Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company’s first product, VeriStrat®, which is used by physicians to help guide therapy for patients ... Read more
May 6, 2010
Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed ... Read more
April 19, 2010
Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone, M.D., Ph.D., Professor of Medicine and Cancer Biology, Vanderbilt University School of Medicine, on Friday, April 30th at the 2nd European Lung Cancer Conference ... Read more
February 5, 2010
Biodesix, Inc. announces that David Brunel, Chief Executive Officer, will present at the 2010 Personalized Medicine Partnerships Conference, Wednesday, February 24th, at 11:00 a.m. eastern time. The conference takes place February 22-24th at the Doubletree Hotel in Philadelphia, PA, and will include presentations by both diagnostic ... Read more
September 28, 2009
Funding to further the commercialization of VeriStrat®
Biodesix, Inc., a privately held molecular diagnostics company focused on proteomic-based diagnostics discovery and commercialization, announced today that it has completed the initial tranche of its $10 million Series B-1 financing round. The financing was led by existing shareholders and ... Read more
May 14, 2009
Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment
Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on ... Read more
